At Yuma Regional Medical Center in Yuma, Arizona, the anatomical pathology lab has adopted cutting edge digital pathology solutions from Ventana Medical Systems, Inc. to increase their efficiencies and to assist in better patient care.

Through innovative solutions for H&E, immunohistochemistry (IHC) and in situ hybridization (ISH), special stains, advanced workflow and digital pathology, Ventana empowers anatomic pathologists and laboratory professionals to increase testing efficiency. Our intuitive, integrated slide staining and workflow management platforms optimize laboratory operations to minimize errors, support diagnosis, and inform treatment decisions for anatomic pathology professional

Anatomic pathology labs today face critical shortages in technicians, along with increasing demands to produce better quality results, faster.While the average pathology lab maintains a 99% quality rate, that leaves a 1% margin for error that could mean as many as 6 misidentified samples every single week for an average size lab*. When real patient results are at risk, even a small margin of error is unacceptable. Now, more than ever, we must safeguard every patient...every step of the way.Here, you will learn about pathology lab process errors that compromise the integrity of patient results, and the solutions that can put your lab on a SaferPath.

Flagship Biosciences  provides quantitative tissue analysis services for pharmaceutical and medical device development. Flagship offers a broad range of tissue assessment options, achieved through a diverse set of approaches. Flagship Biosciences provides tissue analysis solutions to over sixty biotech, pharmaceutical, and medical device clients, with global programs in place for tissue-based companion diagnostics with three of the largest pharmaceutical companies in the world. Their sales grew 400% in 2011, and are on track to triple again in 2012. Flagship scientists published seven peer-reviewed articles in 2011, and filed 4 patent applications during the year. However, the largest development for Flagship was the acquisition of a histology and immunohistochemistry laboratory during the close 2011 which has added tissue procurement to complete their tissue-based analysis operations. Finally, the company’s image analysis technology won a best poster award at the Pathology Visions 2011 conference in San Diego, and a best presentation award at the Pathology Informatics 2011 meeting in Pittsburgh  The company is currently working on a medical device spinout of their existing operations and expansion into Phoenix later this year. Committed to growing not only the company but  also Arizona’s bioscience talent pool, the company currently utilizes many students from Northern Arizona University.  Flagship Biosciences was honored in 2011 with the  2011 AZBio Fast Lane Award .

Kulira Technologies is an advanced biomedical engineering company that designs solutions for surgical oncology using state-of-the-art biomaterials. President and CEO, Xenia Kachur, shares where they've been and where they are going at AZBio Expo 2013.

VENTANA BenchMark Special Stains automated slide stainer eliminates manual processes and temperature dependencies with automated deparaffinization and independent slide heating for histology labs upgrading manual processes or current automation systems

Ventana Medical Systems, Inc., a Member of the Roche Group, is a global leader in tissue diagnostic innovations for anatomic pathology. This video reveals the true story of a quest to improve the standard of care for a single patient -- a quest that began a new era in cancer diagnostics. Discover how automated staining is empowering histology labs worldwide to deliver prompt, personalized diagnostic information.

Thomas M. Grogan, M.D., Founder of Ventana and SVP, Medical Affairs of Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, receives the AZBio Pioneer Award for Lifetime Achievement at the 2013 AZBio Awards on October 10, 2013. Dr. Grogan was a pathologist and professor at the University of Arizona when in the mid 1980’s he and a small team set out to challenge the limitations of the then current standards and processes for cancer pathology.  What was to become the company’s first digital pathology instrument evolved from Grogan’s notes on a yellow pad into the BenchMark IHC/ISH staining platforms.   Under Grogan’s leadership, Ventana was founded in 1987, went public in 1996, and was acquired by Roche for $3.4 billion in 2008. Over the last 25 years, Ventana has grown to become a global leader in developing and manufacturing tissue-based diagnostic instruments and tests focused on the detection of cancer. Ventana employees continue to pursue the same deeply rooted mission of innovating diagnostic testing and enabling personalized healthcare to improve the lives of all patients afflicted with cancer worldwide. Dr. Grogan has made it his personal mission to make life better for the millions of patients who battle cancer each day.  His passion and dedication are infectious and has spread across the company that he and his team built. Through their efforts they have revolutionized the field of cancer diagnostics and are pioneering new roads in the field of personalized healthcare.”